RxDoctor Payments Data

Anas Khanfar, MD

Internal Medicine · New Ulm, MNNPI 1881982494

Payments from drug & device makers

$88in general payments, 2019–2025

Across 4 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$35
  • Pfizer$26
  • E.r. Squibb & Sons, L.L.C.$15
  • Gilead$12

What the payments were for

  • Food & beverage$3540%
  • Education$5360%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$35
Pfizer1$26
E.r. Squibb & Sons, L.L.C.1$15
Gilead1$12

How this compares

$88 in reported general payments places this provider in the 80th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$266,123
Medicare patients
421
Services billed
3,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib26$431,662
XtandiEnzalutamide23$311,811
RevlimidLenalidomide17$291,957
Lenalidomide20$279,958
ZejulaNiraparib Tosylate12$210,428
TagrissoOsimertinib Mesylate12$198,324
IbrancePalbociclib12$192,757
MekinistTrametinib Dimethyl Sulfoxide12$112,091
LapatinibLapatinib Ditosylate12$79,971
EliquisApixaban50$35,226
XareltoRivaroxaban19$14,030
Abiraterone Acetate25$9,177
Imatinib Mesylate31$7,806
Exemestane50$6,226
Anastrozole220$4,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$26$227,98362 claims
AstraZenecaTagrisso$35$198,32412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in New Ulm

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →